CDK6 as a predictive marker of response to fulvestrant treatment and a potential indicator of benefit from CDK4/6 inhibitor therapy in estrogen receptor-positive metastatic breast cancer

Carla Maria Lourenco Alves, Daniel Elias, Maria Bibi Lyng, Martin Bak, Anne E Lykkesfeldt, Henrik Ditzel

Publikation: Konferencebidrag uden forlag/tidsskriftPosterForskningpeer review

OriginalsprogEngelsk
Publikationsdato9. jul. 2016
StatusUdgivet - 9. jul. 2016
Begivenhed24th Biennial Congress of the European Association for Cancer Research - Manchester, Storbritannien
Varighed: 9. jul. 201612. jul. 2016

Konference

Konference24th Biennial Congress of the European Association for Cancer Research
LandStorbritannien
ByManchester
Periode09/07/201612/07/2016

Relaterede Aktiviteter

  • 1 Organisering af eller deltagelse i konference

24 Biennial Congress of the European Association for Cancer Research

Carla Maria Lourenco Alves (Deltager)

9. jul. 201612. jul. 2016

Aktivitet: Deltagelse i faglig begivenhedOrganisering af eller deltagelse i konference

Citationsformater

Alves, C. M. L., Elias, D., Lyng, M. B., Bak, M., Lykkesfeldt, A. E., & Ditzel, H. (2016). CDK6 as a predictive marker of response to fulvestrant treatment and a potential indicator of benefit from CDK4/6 inhibitor therapy in estrogen receptor-positive metastatic breast cancer. Poster session præsenteret på 24th Biennial Congress of the European Association for Cancer Research, Manchester, Storbritannien.